Rafarma Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RAFA research report →
About the company
Rafarma Pharmaceuticals, Inc. is a diversified pharmaceutical enterprise that manufactures and distributes a range of medicinal products, including generic antibiotics and specialized drugs, within the Russian market. Its product portfolio encompasses anti-cancer medications, cephalosporin-derived compounds, and non-beta-lactam antibiotics.
- CEO
- Sergey Brusnitsin
- IPO
- 2012
- Employees
- 700
- HQ
- Sandy, UT, US
Price Chart
- Market Cap
- $1.76M
- P/E
- 10.00
- P/S
- 0.20
- P/B
- 0.17
- EV/EBITDA
- 5.35
- Div Yield
- 0.00%
- Gross Margin
- 6.37%
- Op Margin
- 4.07%
- Net Margin
- 2.50%
- ROE
- 2.13%
- ROIC
- 2.43%
- Revenue
- $9.18M · 1.09%
- Net Income
- $349.00K · 31.20%
- EPS
- $0.00 · 33.33%
- Op Income
- $489.00K
- FCF YoY
- -136.36%
- 52W High
- $0.10
- 52W Low
- $0.00
- 50D MA
- $0.05
- 200D MA
- $0.05
- Beta
- 0.58
- Avg Volume
- 8.81K
Get TickerSpark's AI analysis on RAFA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our RAFA coverage
Recent articles, reports, and earnings notes.
No research on RAFA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RAFA report →Similar companies
Peers in the same neighborhood.